|
PARKINSON'S DISEASE (PD)
Clinical
Parkinson’s Disease affects 1 in
100 of the population. Symptomatic treatment in the form
of L-dopa and dopamine agonists is reasonably effective
for the first few years, but the drugs then lose their
potency and begin to cause troublesome dyskinesias. Dementia,
hallucinations and random periods of severe immobility
begin to supervene in many patients as the disease progresses.
No treatment alters the course of the disease.
There is a need both for symptomatic treatment
with fewer side effects than existing treatments and most
importantly for treatments which slow down disease progression.
DanioLabs approach
DanioLabs is developing compounds which
reverse the motor symptoms, thus allowing lower doses
of L-dopa to be administered. This will help reduced
the long term side effects of dyskinesias and on/off
symptoms. Additionally, compounds are being identified
which slow or arrest the underlying neurodegeneration.
|
